Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

The Marathon of Care: Long-Term Outlook and Monitoring

At a Glance

Managing Central Retinal Vein Occlusion (CRVO) is a long-term process that requires consistent monitoring. While mild CRVO can progress to a severe form, regular treatments and treat-and-extend protocols can help patients maintain functional vision for years by controlling retinal swelling.

Living with Central Retinal Vein Occlusion (CRVO) is often described as a “marathon” rather than a sprint. While the initial diagnosis is a shock, the long-term journey involves a shift toward consistent monitoring and management. Understanding the road ahead can help you navigate the “treatment burden”—the time, energy, and emotional toll of frequent medical care—while maintaining the best possible vision [1][2].

The Realistic Roadmap: Monitoring and Conversion

In the first year, your visits will likely be frequent, often every 4 to 6 weeks, as your doctor works to stabilize the swelling in your eye [1][3].

One critical reason for this close monitoring is that non-ischemic CRVO (the milder form) can “convert” into the more severe ischemic form [4]. This conversion most commonly happens within the first year [4]. Your doctor uses regular exams and scans to catch this early, as it may require a change in treatment, such as more frequent injections or the addition of laser therapy [5][6].

Decoding Your Scans: Predicting the Future

Modern OCT scans do more than just measure swelling; they show the structural health of your retina. Your doctor looks for specific “biomarkers” that act as clues for your long-term visual potential [7][8]:

  • The Ellipsoid Zone (EZ): This is a specific layer in the retina that houses your photoreceptors (the cells that catch light). If the EZ is intact or recovering, it is a very positive sign for your vision [9][7]. If there is EZ disruption, it may explain why your vision remains blurred even after the swelling goes down [9][10].
  • DRIL (Disorganization of Retinal Inner Layers): This term describes when the distinct layers of the retina become blurred together on a scan [11]. A higher degree of DRIL is often a surrogate marker for past ischemia (lack of oxygen) and can predict that vision may not fully return to “normal” despite treatment [11][12].

Managing the Treatment Burden

It is completely normal to feel “burnt out” by the cycle of appointments, scans, and injections [2][13]. Patients often experience “scan anxiety”—the stress of waiting to see if the fluid has returned—or “injection anxiety” [14].

To help manage this marathon, many specialists use a Treat-and-Extend (T&E) protocol [15][16].

  1. Stabilization: You receive injections until the fluid in your macula is gone [15].
  2. Extension: Your doctor gradually adds a week or two between appointments (e.g., from 6 weeks to 8 weeks) [15][17].
  3. Maintenance: If your eye stays dry at the longer interval, you continue that schedule. If fluid returns, the interval is shortened again [15][16].

This approach aims to provide the fewest number of injections while still protecting your vision from the damage caused by recurring swelling [18][15].

Long-Term Outlook

While ischemic CRVO generally has a more challenging prognosis, many patients with non-ischemic CRVO maintain good, functional vision for five years or more with consistent care [1][3]. The key to success is staying “ahead of the fluid” by keeping your appointments, even when your vision feels stable [19][13]. Remember, the goal of treatment is not just to improve vision today, but to preserve the health of your retina for the years to come [1][20].

Common questions in this guide

Can mild CRVO turn into a more severe form?
Yes, non-ischemic CRVO can convert into the more severe ischemic form, most commonly within the first year. This is why frequent monitoring is crucial so your doctor can adjust your treatment, such as increasing injections or adding laser therapy, if needed.
What does EZ disruption or DRIL mean on my OCT scan?
EZ disruption and DRIL are terms used to describe damage to the structural layers of your retina on an imaging scan. A higher degree of these markers suggests past damage and indicates that your vision may not fully return to normal, even after treatment.
What is the treat-and-extend protocol for CRVO?
Treat-and-extend is a strategy to reduce your number of office visits. Once initial injections stabilize the fluid in your eye, your doctor gradually increases the time between appointments to find the longest interval that keeps your vision stable.
How long will I need treatment for CRVO?
Managing CRVO is a long-term process, and many patients maintain functional vision for five years or more with consistent care. You will likely have frequent appointments in the first year, which may be spaced out over time if your eye remains stable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Looking at my latest OCT, do you see any 'EZ disruption' or 'DRIL', and what does that mean for my visual potential?
  2. 2.Has my CRVO shown any signs of converting from non-ischemic to ischemic?
  3. 3.Based on my progress, are we able to move toward a 'treat-and-extend' schedule to reduce the frequency of my visits?
  4. 4.How long do you anticipate I will need to continue with regular injections?
  5. 5.What is the long-term plan if my macular edema becomes resistant to the current medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors.

    Spooner K, Fraser-Bell S, Hong T, Chang AA

    BMJ open ophthalmology 2019; (4(1)):e000249 doi:10.1136/bmjophth-2018-000249.

    PMID: 30997407
  2. 2

    Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.

    Kulikov AN, Vasiliev AS, Kalinicheva YA, Maltsev DS

    BMC ophthalmology 2024; (24(1)):369 doi:10.1186/s12886-024-03650-z.

    PMID: 39180057
  3. 3

    Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

    Chatziralli I, Theodossiadis G, Theodossiadis P

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2017; (255(7)):1459-1460 doi:10.1007/s00417-017-3682-1.

    PMID: 28484833
  4. 4

    USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC.

    Thomas AS, Thomas MK, Finn AP, Fekrat S

    Retina (Philadelphia, Pa.) 2019; (39(6)):1033-1038 doi:10.1097/IAE.0000000000002126.

    PMID: 29474305
  5. 5

    ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ERA.

    Tam EK, Golchet P, Yung M, et al.

    Retina (Philadelphia, Pa.) 2018; (38(2)):292-298 doi:10.1097/IAE.0000000000001546.

    PMID: 28207609
  6. 6

    Central retinal thickness changes and risk of neovascular glaucoma after intravitreal bevacizumab injection in patients with central retinal vein occlusion.

    Lee YH, Kim YC

    Scientific reports 2022; (12(1)):2051 doi:10.1038/s41598-022-06121-x.

    PMID: 35136171
  7. 7

    Predicting response of ischemic central retinal vein occlusion to bevacizumab injections: 1 year follow-up.

    Segal O, Mimouni M, Rabina G, et al.

    International ophthalmology 2021; (41(2)):533-540 doi:10.1007/s10792-020-01604-0.

    PMID: 33094440
  8. 8

    OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.

    Tang F, Qin X, Lu J, et al.

    Retina (Philadelphia, Pa.) 2020; (40(4)):773-785 doi:10.1097/IAE.0000000000002444.

    PMID: 30640282
  9. 9

    Evaluation of the Initial Optical Coherence Tomography Parameters in Anticipating the Final Visual Outcome of Central Retinal Vein Occlusion.

    Ozer MD, Batur M, Mesen S, et al.

    Journal of current ophthalmology 2020; (32(1)):46-52 doi:10.4103/JOCO.JOCO_47_20.

    PMID: 32510013
  10. 10

    Evaluation of Anatomical and Tomographic Biomarkers as Predictive Visual Acuity Factors in Eyes with Retinal Vein Occlusion Treated with Dexamethasone Implant.

    Covello G, Maglionico MN, Figus M, et al.

    Journal of clinical medicine 2024; (13(15)) doi:10.3390/jcm13154533.

    PMID: 39124798
  11. 11

    Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion.

    Berry D, Thomas AS, Fekrat S, Grewal DS

    Ophthalmology. Retina 2018; (2(11)):1125-1132 doi:10.1016/j.oret.2018.04.019.

    PMID: 30511035
  12. 12

    Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis.

    Johari M, Attar A, Eghtedari D, Razavizadegan SA

    BMC ophthalmology 2024; (24(1)):30 doi:10.1186/s12886-024-03298-9.

    PMID: 38254100
  13. 13

    Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.

    Holekamp NM, Campbell J, Almony A, et al.

    American journal of ophthalmology 2018; (191()):83-91 doi:10.1016/j.ajo.2018.04.010.

    PMID: 29684329
  14. 14

    Impact of Anxiety Levels and Sleep Patterns on Perceived Pain During Intravitreal Bevacizumab Injections.

    Wieder MS, Szlechter M, Fischman N, et al.

    Ophthalmic surgery, lasers & imaging retina 2021; (52(9)):498-504 doi:10.3928/23258160-20210819-02.

    PMID: 34505802
  15. 15

    INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial.

    Casselholm de Salles M, Amrén U, Kvanta A, Epstein DL

    Retina (Philadelphia, Pa.) 2019; (39(7)):1370-1376 doi:10.1097/IAE.0000000000002171.

    PMID: 29624543
  16. 16

    Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion.

    Nghiem-Buffet S, Glacet-Bernard A, Addou-Regnard M, et al.

    Journal of ophthalmology 2018; (2018()):8656495 doi:10.1155/2018/8656495.

    PMID: 30116635
  17. 17

    Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.

    Pfau M, Fassnacht-Riederle H, Becker MD, et al.

    Ophthalmic research 2015; (54(3)):150-6 doi:10.1159/000439223.

    PMID: 26413794
  18. 18

    Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.

    Korobelnik JF, Larsen M, Eter N, et al.

    American journal of ophthalmology 2021; (227()):106-115 doi:10.1016/j.ajo.2021.01.027.

    PMID: 33556381
  19. 19

    Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.

    Gurudas S, Patrao N, Nicholson L, et al.

    JAMA ophthalmology 2022; (140(2)):143-150 doi:10.1001/jamaophthalmol.2021.5619.

    PMID: 34989804
  20. 20

    Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

    Chatziralli I, Theodossiadis G, Moschos MM, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2017; (255(6)):1093-1100 doi:10.1007/s00417-017-3613-1.

    PMID: 28214955

This page provides educational information about CRVO long-term care and monitoring. It is not medical advice. Always consult your ophthalmologist or retina specialist for personalized guidance regarding your vision.

Get notified when new evidence is published on Central retinal vein occlusion.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.